LuciCaboz — Cabozantinib 20 mg, 90 pcs, Lucius

LuciCaboz — Cabozantinib Tablets 20 mg, 90 Tablets

Product code: 505

22350₴ 24362₴ -8% On order · from 10 days

Analogues

1
Active ingredient
Dosage form Tablets
Tablets per pack 90

LuciCaboz is a potent multi-targeted antineoplastic agent belonging to the kinase inhibitor class, indicated for the treatment of renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. The active pharmaceutical ingredient is cabozantinib at a strength of 20 mg supplied as film-coated oral tablets (Cabozantinib Tablets 20 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Cabozantinib is an oral multi-tyrosine kinase inhibitor that suppresses the activity of critical receptors involved in tumor angiogenesis, growth, and metastasis, including VEGFR (1, 2, 3), MET, AXL, and RET. Blocking these signaling pathways leads to tumor shrinkage, reduced blood supply to the neoplasm's vascular network, and the overcoming of drug resistance. The low 20 mg strength is particularly convenient for precise dose adjustment and titration when managing adverse events.

Supplied in a package containing 90 tablets of 20 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciCaboz 20 mg:

  • ✅ Multi-Targeted Action: Simultaneous inhibition of VEGFR, MET, AXL, and RET for maximal tumor control.
  • ✅ Dosing Flexibility: The 20 mg strength enables smooth and precise dose adjustments for individual tolerability.
  • ✅ Broad Indication Spectrum: Proven efficacy in renal cancer, liver cancer, and thyroid cancer.
  • ✅ Convenient Oral Dosing: Taken orally once daily.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Cabometyx).

LuciCaboz is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Cabozantinib (as cabozantinib S-malate) — 20 mg.
  • Excipients: Microcrystalline cellulose, anhydrous lactose, hydroxypropyl cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate. Coating: hypromellose, titanium dioxide, triacetin, iron oxide yellow.

Packaging and Presentation: Film-coated tablets, 20 mg strength. Each package contains 90 tablets along with prescribing information. Labeled with LuciCaboz (Cabozantinib Tablets 20 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Cabozantinib is a tyrosine kinase inhibitor that targets MET (hepatocyte growth factor receptor), VEGFR (1, 2, 3), AXL, and RET. These receptor tyrosine kinases are involved in both normal cellular processes and pathological angiogenesis, tumor growth, metastasis, and drug resistance. Inhibition of these targets results in decreased tumor vessel growth and cancer cell apoptosis.

Pharmacokinetics:

  • Absorption: Following oral administration, cabozantinib absorption is relatively slow; peak plasma concentration (Tmax) is achieved within approximately 2 to 5 hours. High-fat meals significantly increase systemic drug exposure.
  • Distribution: Human plasma protein binding is very high (approx. 99.7%).
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 and the transport protein MRP2.
  • Elimination: Excreted predominantly via feces (approx. 54% as metabolites) and renally (approx. 27%). Terminal elimination half-life (T1/2) averages approximately 55 hours.

LuciCaboz is indicated in adult patients for:

  • Renal Cell Carcinoma (RCC): Monotherapy for advanced renal cell carcinoma in first-line settings or following prior VEGFR-targeted therapy.
  • Hepatocellular Carcinoma (HCC): Treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.
  • Medullary Thyroid Cancer (MTC): Treatment of unresectable locally advanced or metastatic medullary thyroid cancer.

LuciCaboz is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard dose for renal cell carcinoma and hepatocellular carcinoma is 60 mg once daily (e.g., three 20 mg tablets). For medullary thyroid cancer, the recommended dose is 140 mg once daily. The low 20 mg strength facilitates individual dose titration and reduction when managing adverse events.

Administration Guidelines:
Tablets must be taken on an empty stomach — at least 1 hour before or 2 hours after a meal (avoid food intake for 2 hours prior and 1 hour post-dose). Swallow tablets whole; do not break or crush.

Administration of LuciCaboz is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to cabozantinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction (Child-Pugh Class C).

Cabozantinib is metabolized primarily via CYP3A4:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): May elevate cabozantinib plasma concentrations and toxicity risks (avoid concurrent use).
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease cabozantinib blood concentrations and reduce efficacy (avoid concurrent use).
  • MRP2 Inhibitors: Drugs inhibiting MRP2 transporters may increase systemic cabozantinib exposure.

Pregnancy:
LuciCaboz is contraindicated during pregnancy. Based on its mechanism of action, cabozantinib may cause severe developmental defects and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 4 months following the final dose.

Lactation:
Excretion of cabozantinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Skin and Subcutaneous Tissue Disorders: Palmar-plantar erythrodysesthesia (hand-foot syndrome), rash, dry skin, alopecia.
  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, stomatitis, abdominal pain, constipation, decreased appetite.
  • Cardiovascular System: Arterial hypertension (regular blood pressure monitoring required), thromboembolic events.
  • General Disorders: Fatigue, asthenia, weight loss, dysphonia (hoarseness).
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), thrombocytopenia, lymphopenia, hypokalemia, proteinuria.

Symptoms:
Specific acute overdose symptoms of cabozantinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (severe dermatologic reactions, diarrhea, hypertension, and elevated liver function test parameters).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under strict medical monitoring.

Storage Requirements for LuciCaboz 20 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciCaboz 20 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Cabozantinib Tablets 20 mg, and 90 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00